New research led by Guohua Li reveals that Medicaid beneficiaries with autism have significantly shorter lifespans than both other Medicaid beneficiaries and the general population, highlighting substantial health challenges faced by this vulnerable group throughout their lives.
A new modeling study published in The Lancet suggests that US Medicare's most-favored-nation pricing policy, which ties Medicare payments to prices in other high-income countries, could reduce US spending on brand-name drugs but incentivize pharmaceutical companies to increase prices or delay launches in lower-price markets like Europe.
A federal appeals court ruled the Justice Department can proceed with a subpoena against a Washington state provider of gender-affirming care to minors, while the Centers for Medicare and Medicaid Services ended federal Medicaid funding for such treatments. The moves are part of the Trump administration's broader campaign to restrict transgender healthcare for young people.
Brookings Institution researchers have criticized the Centers for Medicare and Medicaid Services for allegedly using faulty assumptions in a rule that made it harder for sick Medicaid enrollees to prove exemption from work requirements. The rule has already drawn lawsuits.
The Trump administration finalized a rule ending Medicaid and CHIP funding for gender-affirming surgeries and hormone treatments for transgender minors. The policy change, announced Tuesday, is the latest in a series of actions by the administration targeting transgender people.
Federal officials have imposed a Medicaid funding freeze on California and are threatening similar action against other states, representing a significant escalation in federal-state healthcare policy conflicts.
The Trump administration disclosed plans to reduce Medicaid state directed payments to providers even more than Congress already slashed, setting up a probable confrontation with healthcare provider groups.
The Centers for Medicare & Medicaid Services and FDA announced a new pathway to streamline Medicare coverage for breakthrough medical devices, cutting red tape and providing predictability for device manufacturers and faster patient access to life-changing technologies.
